使用Erenumab治疗偏头痛:能否导致认知和心理质量改善?
Michele Torrisi1, Francesco Corallo1, Viviana Lo Buono1
1IRCCS Centro Neurolesi "Bonino-Pulejo" S.S. 113 Via Palermo, C/da Casazza, 98124 Messina, Italy.
Medicina (Kaunas, Lithuania)
|May 27, 2023
概括
埃雷努马布是一种单克隆抗体,向素基因相关 (CGRP),显著改善了偏头痛患者的认知功能和生活质量. 这种治疗也减少了偏头痛的残疾,提供了一个有前途的治疗选择.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是一种高度残疾的神经系统疾病,影响生活质量.
- 针对素基因相关 (CGRP) 的单克隆抗体已经成为先进的偏头痛预防策略.
- 作为CGRP受体对抗剂的Erenumab在偏头痛管理中显示出治疗效果和耐受性.
研究的目的:
- 评估 erenumab 对偏头痛患者认知表现的影响.
- 评估埃伦乌马布对心理健康和生活质量的影响.
- 确定埃伦乌马布在减少偏头痛相关残疾方面的有效性.
主要方法:
- 一项追溯试点研究,涉及14名偏头痛患者.
- 通过临床和心理测试评估认知和心理功能.
- 基线和随访得分的比较,以衡量治疗效果.
主要成果:
- 在全球认知表现上观察到显著的改善.
- 患者报告说,在接受埃伦乌马布治疗后,他们的生活质量得到改善.
- 记录了偏头痛残疾人的显着减少.
结论:
- 埃雷努马布治疗导致了偏头痛患者认知功能和生活质量的显著改善.
- 埃雷努马布显示出作为治疗剂的潜力,可以增强偏头痛患者的整体幸福感.
- 这些发现支持埃伦马布在管理偏头痛残疾和相关认知和心理障碍方面的作用.
相关概念视频
Electroconvulsive Therapy
83
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
83
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
166
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
166


